Literature DB >> 32283061

Expression analysis of vimentin and the related lncRNA network in breast cancer.

Mehdi Mohebi1, Soudeh Ghafouri-Fard2, Mohammad Hossein Modarressi3, Sepideh Dashti1, Ali Zekri4, Vahid Kholghi-Oskooei5, Mohammad Taheri6.   

Abstract

Vimentin (VIM) is a mesenchymal marker which is expressed in some cancer types including breast cancer. A long non-coding RNA (lncRNA) has been identified to be transcribed from VIM gene locus and positively regulate expression of VIM. This lncRNA has been named as VIM-antisense 1 (VIM-AS1). Expression of VIM is also regulated by another lncRNA namely AGAP2-antisense RNA 1 (AGAP2-AS1). In the current study, we aimed at identification of the expression pattern of VIM, VIM-AS1, AGAP2 and AGAP2-AS1 in 78 breast cancer samples and their paired adjacent non-cancerous tissues (ANCTs) by means of real time PCR. All mentioned genes were significantly down-regulated in tumoral tissues compared with ANCTs (P values less than 0.000). Relative expression of VIM-AS1 in tumoral tissues versus ANCTs was associated with menopause age (P = .02) in a way that this gene was down-regulated in most of patients whose menopause age was between 40 and 50 years. Moreover, AGAP2-AS1 relative expression was associated with patients' body mass index (P = .03). There were trends toward association between VIM relative expression and tumor size (P = .07) and association between VIM-AS1 relative expression and obesity (P = .06). Expression of VIM was significantly higher in tumoral tissues of patients who had history of hormone replacement therapy compared with those without such history (P = .03). Moreover, expression levels of both VIM and AGAP2-AS1 were lower in patients whose menarche age was between 10 and 12 years old compared with those whose menarche age was between 13 and 15 years old (P values = .01 and 0.04, respectively). Transcript quantities of VIM, VIM-AS1, AGAP2 and AGAP2-AS1 were correlated with each other both in tumoral tissues and in ANCTs. Among four assessed genes, AGAP2 had the best diagnostic power for discrimination of tumoral tissues from ANCTs (AUC value = 0.87). Combination of four genes led to enhancement of AUC value to 0.94. The current study shows the importance of VIM and its associated lncRNAs in breast cancer and potentiates these genes as biomarkers for this malignancy. Moreover, these lncRNAs might be regarded as therapeutic targets in breast cancer.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  AGAP2; AGAP2-AS1; Breast cancer; VIM; VIM-AS1

Year:  2020        PMID: 32283061     DOI: 10.1016/j.yexmp.2020.104439

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  9 in total

1.  A Seven Immune-Related lncRNAs Model to Increase the Predicted Value of Lung Adenocarcinoma.

Authors:  Jian-Ping Li; Rui Li; Xiao Liu; Chen Huo; Ting-Ting Liu; Jie Yao; Yi-Qing Qu
Journal:  Front Oncol       Date:  2020-10-14       Impact factor: 6.244

2.  Suppression of circulating AP001429.1 long non-coding RNA in obese patients with breast cancer.

Authors:  Hani Choudhry; Mohammed A Hassan; Abdulrahman L Al-Malki; Kaltoom A Al-Sakkaf
Journal:  Oncol Lett       Date:  2021-05-03       Impact factor: 2.967

3.  LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis.

Authors:  Peng Zhao; Jianhua Cheng; Bin Li; Ding Nie; Hongyun Wang; Chuzhong Li; Songbai Gui; Yazhuo Zhang
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

4.  A Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer.

Authors:  Zhaojing Jiang; Jingyu Li; Wenqing Feng; Yujie Sun; Junguo Bu
Journal:  J Oncol       Date:  2022-02-08       Impact factor: 4.375

5.  Necroptosis-related lncRNA signatures determine prognosis in breast cancer patients.

Authors:  Yuan Zhang; Qingfang Yue; Fei Cao; YanQin Li; Yifang Wei
Journal:  Sci Rep       Date:  2022-07-04       Impact factor: 4.996

6.  MiR-630 suppresses non-small cell lung cancer by targeting vimentin.

Authors:  Bin Wang; Jie Li; Yulin Li; Tao Liang; Xiangyang Chu
Journal:  J Clin Lab Anal       Date:  2022-07-15       Impact factor: 3.124

7.  Nondestructive protein sampling with electroporation facilitates profiling of spatial differential protein expression in breast tumors in vivo.

Authors:  Edward Vitkin; Amrita Singh; Zohar Yakhini; Alexander Golberg; Julia Wise; Shay Ben-Elazar
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

8.  Expression Analysis of Long Non-Coding RNAs Related With FOXM1, GATA3, FOXA1 and ESR1 in Breast Tissues.

Authors:  Bita Hassani; Mohammad Taheri; Yazdan Asgari; Ali Zekri; Ali Sattari; Soudeh Ghafouri-Fard; Farkhondeh Pouresmaeili
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

Review 9.  Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System.

Authors:  Soudeh Ghafouri-Fard; Amin Agabalazadeh; Atefe Abak; Hamed Shoorei; Mohammad Mehdi Hassanzadeh Taheri; Mohammad Taheri; Guive Sharifi
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.